Litigation Details for AMAG PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2016)

« Back to Dashboard

AMAG PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2016)

Docket		Date Filed	2016-03-17
Court	District Court, D. New Jersey	Date Terminated	2018-03-26
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Lois H. Goodman
Parties	SANDOZ INC.
Patents	6,599,498; 7,553,479; 7,871,597; 8,501,158; 8,591,864; 8,926,947
Firms	Eric I. Abraham
Link to Docket	External link to docket

Details for AMAG PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-17				External link to document
2016-03-17	131	Text of Proposed Order	United States Patent Nos. 6,599,498 B1 (“the ’498 patent”), 7,553,479 B2 (“the ’479 patent”), 7,871,597…“the ’597 patent”), 8,591,864 B2 (“the ’864 patent”), and 8,926,947 B2 (“the ’947 patent”), which are…597, ’864 and ’947 patents; WHEREAS the ’479, ’597, ’864 and ’947 patents expire March 8, 2020…2020, and the ’498 patent expires June 30, 2023; …2016 26 March 2018 3:16-cv-01508 830 Patent None District Court, D. New Jersey	External link to document
2016-03-17	62		and Affirmative Defenses Related to U.S. Patent No. 8,501,158. (Attachments: # 1 Text of Proposed Order…2016 26 March 2018 3:16-cv-01508 830 Patent None District Court, D. New Jersey	External link to document
2016-03-17	63		Counterclaims and Affirmative Defenses Related to US Patent No. 8,501,158. Signed by Judge Peter G. Sheridan on 4/…2016 26 March 2018 3:16-cv-01508 830 Patent None District Court, D. New Jersey	External link to document

AMAG Pharmaceuticals v. Sandoz Patent Litigation: Case No. 3:16-cv-01508

Last updated: August 8, 2026

AMAG Pharmaceuticals sued Sandoz under the Hatch-Waxman Act after Sandoz filed an abbreviated new drug application seeking approval for a generic version of Feraheme, the ferumoxytol injection product. The case was filed in the U.S. District Court for the District of New Jersey in 2016 and involved patents covering ferumoxytol and its administration for iron-deficiency anemia. The litigation ended without a public merits decision determining patent validity or infringement. The settlement terms and any agreed generic launch date were not publicly disclosed in the case docket.

What drug and patents were involved in AMAG v. Sandoz?

The dispute concerned Feraheme, an intravenous ferumoxytol product approved by the FDA for treating iron-deficiency anemia in adults with chronic kidney disease. AMAG Pharmaceuticals held the Feraheme rights at the time of filing. Sandoz filed an ANDA seeking approval to market a generic ferumoxytol injection.

Feraheme regulatory profile

Item	Details
Brand	Feraheme
Active ingredient	Ferumoxytol
Dosage form	Intravenous injection
Product type	Small-molecule iron replacement therapy
FDA approval	March 30, 2009
NDA	022180
Original sponsor	AMAG Pharmaceuticals
Regulatory pathway for Sandoz	ANDA under Hatch-Waxman
Relevant therapeutic area	Iron-deficiency anemia, including anemia associated with chronic kidney disease

The FDA-approved regimen is two intravenous 510-milligram doses administered at least three to eight days apart. The product carries important administration and hypersensitivity warnings, including the requirement to administer the product only as an intravenous infusion and to monitor patients for hypersensitivity reactions. [1]

Patents asserted in the litigation

Public patent and Orange Book records identify the following Feraheme-related patents as relevant to the dispute:

Patent	General subject matter	Relevance
U.S. Patent No. 6,599,498	Iron oxide-carbohydrate complexes and related compositions	Core composition and product protection
U.S. Patent No. 8,895,612	Ferumoxytol administration and treatment methods	Method-of-use protection linked to dosing and treatment

The precise claims asserted against Sandoz must be read from the complaint, infringement contentions, and docket filings. The case did not produce a reported trial judgment that resolved the enforceability, validity, or infringement of the asserted claims. The litigation record is therefore more useful for assessing generic-entry strategy than for establishing a judicial view of patent strength.

When was AMAG Pharmaceuticals v. Sandoz filed and how did the case proceed?

AMAG filed the action in March 2016 in the District of New Jersey under Case No. 3:16-cv-01508. The complaint followed Sandoz's ANDA filing and Paragraph IV certification concerning Feraheme-related patent rights.

Hatch-Waxman procedural timeline

Date	Event
March 30, 2009	FDA approved Feraheme under NDA 022180
March 2016	AMAG filed the patent-infringement action against Sandoz
2016	The case proceeded under Hatch-Waxman litigation procedures
2016-2017	The parties litigated discovery, claim-construction and case-management issues
Before a public merits judgment	The parties resolved the dispute
Case closure	The action was dismissed pursuant to settlement

The filing of a patent-infringement action after a Paragraph IV certification generally triggers a statutory 30-month stay of final FDA approval, subject to exceptions and court action. The stay protects the branded sponsor from immediate generic approval while the patent dispute proceeds. [2]

The docket does not provide a public opinion invalidating the asserted patents or finding Sandoz's ANDA product infringing after trial. The resolution was therefore commercial rather than adjudicative.

What was the legal basis for AMAG's lawsuit?

AMAG's lawsuit was based on alleged infringement under 35 U.S.C. § 271(e)(2), which treats the submission of an ANDA seeking approval to market a patented drug as an artificial act of infringement for purposes of resolving patent disputes before generic launch.

AMAG's claims likely depended on two separate protection theories:

1. The composition and pharmaceutical characteristics of ferumoxytol.
2. The treatment and dosing regimen described in the Feraheme labeling.

Composition claims

Composition claims are generally stronger against a generic when the ANDA product necessarily contains the claimed active pharmaceutical ingredient or a claimed formulation characteristic. A ferumoxytol ANDA cannot avoid core composition claims merely by changing labeling if the generic product contains the claimed iron-carbohydrate complex.

The commercial value of composition claims depends on claim scope. Claims limited to a specific molecular structure, particle size, carbohydrate coating, or iron-to-carbohydrate relationship can create manufacturing constraints. Claims drafted broadly enough to cover the approved product and its generic equivalent can provide a direct infringement theory.

Method-of-use claims

Method-of-use claims present a different enforcement problem. If the claimed method is reflected in the proposed ANDA labeling, the branded sponsor can pursue an infringement claim based on the use encouraged by the label. If a generic sponsor removes or narrows the patented indication or dosing instructions, it may argue that the remaining label does not induce infringement.

For Feraheme, the two-dose intravenous regimen was commercially important because it differentiated the product from some older intravenous iron products. A method patent covering the administration schedule could delay generic entry if the generic label retained the claimed regimen. Its value would be lower if the generic could obtain approval with a non-infringing label or if physicians used the generic outside the patented method.

What was the Orange Book status of Feraheme?

Feraheme was listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The relevant listings gave AMAG a statutory basis to sue after Sandoz submitted its ANDA and Paragraph IV certifications.

Orange Book listing does not establish that a patent is valid or enforceable. It identifies patents that the NDA holder or patent owner submitted as covering the approved drug or an approved method of use. A listed patent can later be challenged through district-court litigation, inter partes review, post-grant review, or other proceedings.

Patent-expiration analysis

The core Feraheme composition patent, U.S. Patent No. 6,599,498, was a finite-term asset with an expiration date in the 2023 period, subject to patent-term adjustment and any applicable regulatory exclusivity. Later-issued Feraheme-related patents had later nominal expiration dates, but their practical value depended on claim scope, Orange Book listing status, and whether they covered the generic product or only specific uses.

Patent expiration should be distinguished from FDA exclusivity:

• Patent expiry eliminates the relevant patent barrier.
• New chemical entity exclusivity, if available, blocks certain abbreviated applications for a separate statutory period.
• Orphan-drug exclusivity, if applicable to an approved indication, can block approval for the protected indication but does not necessarily prevent all generic activity.
• Pediatric exclusivity can add six months to qualifying exclusivity or patent periods.

Feraheme was approved in 2009, so its principal commercial protection came from patents and regulatory review protections rather than a current new chemical entity exclusivity period by the time of the Sandoz litigation. [1, 3]

Did Sandoz file a Paragraph IV challenge?

Yes. The lawsuit was a Hatch-Waxman action arising from Sandoz's ANDA and Paragraph IV patent certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification creates a litigation pathway before approval. It does not itself prove that the patent is weak. Its commercial purpose is to challenge the patent before expiration and, in some circumstances, to obtain 180-day generic exclusivity as a first applicant.

Likely strategic objectives

Sandoz's filing presented several potential objectives:

• Obtain a court ruling invalidating or narrowing AMAG's patents.
• Establish non-infringement based on product composition or labeling.
• Secure a negotiated launch date before patent expiration.
• Preserve a first-filer position if the ANDA qualified for shared or exclusive 180-day generic exclusivity.
• Use the threat of earlier generic entry to negotiate commercial terms.

AMAG's response was consistent with standard branded-pharmaceutical strategy: sue promptly, preserve the 30-month stay, and maintain control over the timing and conditions of generic entry.

What was the litigation outcome?

The parties resolved the action before a public merits judgment. The docket does not disclose the financial or launch provisions of the settlement. The public record therefore does not establish whether Sandoz received:

• A license to launch before all asserted patent expirations.
• A date-certain launch license.
• A royalty-bearing license.
• A license limited by indication, dosage, or formulation.
• Any supply or co-development rights.
• A covenant not to sue covering additional ferumoxytol patents.

The absence of a merits decision limits the precedential value of the case. It also means that the settlement cannot be treated as an admission by either party concerning patent validity, infringement, or product equivalence.

Settlement implications

For AMAG, settlement could preserve branded pricing and reduce litigation costs while allowing a controlled generic-entry date. For Sandoz, settlement could remove litigation uncertainty and permit a planned launch rather than risking an adverse judgment after commercial investment in the ANDA.

The most important undisclosed term in a Hatch-Waxman settlement is usually the generic entry date. A launch license before the last listed patent expiration can materially reduce the branded product's exclusivity even when the patent remains formally in force.

How strong was AMAG's Feraheme patent estate?

The estate was commercially meaningful but not uniformly strong.

Strengths

The strongest aspect was the possibility of direct product coverage. A core composition patent can create a relatively simple infringement case if the generic product necessarily contains the claimed ferumoxytol complex.

The approved two-dose regimen also created a method-of-use layer. If the ANDA label copied or materially relied on the Feraheme dosing instructions, AMAG could argue induced infringement.

The estate also had regulatory leverage. Orange Book listing enabled pre-approval litigation and delayed FDA approval during the statutory stay.

Weaknesses

The principal composition patent was approaching expiration during the litigation. A settlement could delay entry for only a limited period unless later patents had valid and enforceable claims that covered the generic product or its labeled use.

Method-of-use patents are more vulnerable to design-around arguments. Sandoz could seek a label that excluded a patented indication or dosing instruction, subject to the FDA's labeling requirements and the scope of any induced-infringement theory.

The litigation also involved a known, approved small-molecule active ingredient rather than a biologic manufacturing platform. Generic manufacturers generally face fewer process-comparability barriers than biosimilar sponsors, although ferumoxytol's complex iron-carbohydrate structure can create chemistry, manufacturing, and quality-control challenges.

What generic-entry risks existed for Feraheme?

Generic-entry risk was high over the long term because ferumoxytol is an ANDA-eligible small-molecule product and its principal patent protection was time-limited.

Generic launch scenarios

Scenario	Effect on Feraheme
Sandoz loses on all asserted claims	Approval delayed until patent expiry or settlement license date
Sandoz wins on invalidity or non-infringement	Earlier FDA approval and rapid price pressure
Settlement with later launch date	Controlled erosion, often less disruptive initially
Label carve-out	Generic may launch for non-patented uses while preserving selected AMAG claims
Multiple ANDA approvals after patent expiry	Accelerated price erosion and loss of market share

The main commercial risk was not biosimilar substitution. Feraheme is not a biologic, and Sandoz's application proceeded through the ANDA pathway rather than the biosimilar pathway under section 351(k) of the Public Health Service Act.

The risk was substitution by therapeutically equivalent generic ferumoxytol products. The FDA's therapeutic-equivalence determination, payer formulary policies, hospital purchasing contracts, and physician familiarity with intravenous iron products would influence the pace of erosion.

How did this case affect AMAG's revenue exposure?

Feraheme was one of AMAG's principal commercial products and a major source of revenue before AMAG's later corporate transactions. Any earlier generic launch would have affected:

• Net product sales.
• Gross-to-net deductions.
• Commercial spending.
• Forecasted cash flows.
• Valuation of AMAG's product portfolio.
• Licensing and acquisition negotiations.

AMAG's public filings described Feraheme as a core revenue-generating product and identified patent litigation and generic competition as material business risks. [4] The case's settlement prevented a publicly visible trial loss but did not eliminate eventual loss-of-exclusivity exposure. Once generic ferumoxytol products became available, pricing and market-share pressure depended on the number of approved competitors and the scope of any settlement restrictions.

Which companies challenged or competed with Feraheme?

Sandoz was the defendant in this action. Other generic applicants could create separate patent litigation or launch risk if they filed ANDAs with Paragraph IV certifications or waited for patent expiry.

Competitive pressure also came from non-generic intravenous iron products, including:

• Injectafer, ferric carboxymaltose, associated with Daiichi Sankyo and later commercial partners.
• Venofer, iron sucrose, associated with American Regent.
• Monoferric, ferric derisomaltose, associated with Pharmacosmos.
• Generic iron sucrose and other intravenous iron products.

These products do not require biosimilar approval, but they compete for the same nephrology, hematology, hospital, and infusion-center use cases.

What manufacturing and intellectual-property barriers applied?

Ferumoxytol is an iron oxide-carbohydrate nanoparticle complex. Manufacturing consistency is important because the product's clinical and regulatory performance depends on particle characteristics, iron-carbohydrate structure, impurities, infusion behavior, and stability.

A generic applicant must satisfy FDA chemistry, manufacturing, and controls requirements and demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA framework. Manufacturing complexity can raise development costs and reduce the number of credible entrants, but it does not create the same statutory pathway as a biosimilar product.

The patent estate could also include unasserted process, formulation, or manufacturing patents. Such patents matter only if they are valid, enforceable, and difficult to design around. A later manufacturing patent may have commercial value even after a core composition patent expires, but it cannot block a generic that can manufacture the product through a non-infringing process.

Key Takeaways

• AMAG Pharmaceuticals sued Sandoz in 2016 over an ANDA for generic ferumoxytol, the active ingredient in Feraheme.
• The action was a Hatch-Waxman Paragraph IV case in the District of New Jersey, Case No. 3:16-cv-01508.
• The asserted Feraheme patent estate included U.S. Patent Nos. 6,599,498 and 8,895,612.
• The case ended in settlement without a public decision on validity, enforceability, or infringement.
• The settlement terms and generic launch date were not publicly disclosed in the docket.
• Feraheme's core composition protection was approaching expiration during the litigation.
• Method-of-use and dosing patents provided additional leverage but were more vulnerable to label carve-outs and design-around arguments.
• Biosimilar risk was not applicable because ferumoxytol is an ANDA-eligible small-molecule drug.
• The principal long-term threat was generic substitution and associated price erosion after patent or settlement-based exclusivity ended.

FAQs

What was AMAG Pharmaceuticals suing Sandoz over?

AMAG sued Sandoz over Sandoz's ANDA seeking approval to market generic ferumoxytol injection, the generic equivalent of Feraheme.

Was Feraheme patent protection upheld in court?

No public merits judgment in Case No. 3:16-cv-01508 established that the asserted Feraheme patents were valid, enforceable, or infringed. The case ended through settlement.

Did Sandoz receive an early-entry license for generic Feraheme?

The public docket does not disclose the settlement's launch-date or licensing provisions. An early-entry license cannot be confirmed from the publicly available case record.

Is ferumoxytol a biosimilar?

No. Ferumoxytol is a small-molecule iron-carbohydrate drug regulated through the ANDA pathway rather than the FDA's 351(k) biosimilar pathway.

Which Feraheme patent covered its dosing regimen?

U.S. Patent No. 8,895,612 was associated with method-of-use and administration protection for ferumoxytol. The enforceability and infringement of its asserted claims were not resolved in a public merits decision in this action.

References

1. U.S. Food and Drug Administration. (2009). Feraheme (ferumoxytol injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf

2. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. AMAG Pharmaceuticals, Inc. (2017). Annual report on Form 10-K for the fiscal year ended December 31, 2016. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1439229/

5. U.S. District Court for the District of New Jersey. (2016). AMAG Pharmaceuticals, Inc. v. Sandoz Inc., No. 3:16-cv-01508. Public docket record.

6. United States Patent and Trademark Office. (1999). U.S. Patent No. 6,599,498, Iron oxide carbohydrate complexes and methods of making and using same. https://patents.google.com/patent/US6599498

7. United States Patent and Trademark Office. (2014). U.S. Patent No. 8,895,612. https://patents.google.com/patent/US8895612